Abstract:Objective To compare the therapeutic effect of TACE combined with or without endovascular implantation of iodine-125 seeds strand for hepatocellular carcinoma ( HCC) with extensive portal vein tumor thrombus(PVTT)with randomized design.Methods From May-2011 to Dec 2012,62 patients of HCC with extensive PVTT who received TACE were randomized divided into group A ( conbined with , 30 cases)and group B(without,32 cases)endovascular implantation of iodine-125 seeds strand were analyzed retrospectively .TACE was performed after the iodine-125 seed strand implanted in the target segment of PVTT.Adverse events , laboratory tests and abdominal constrast CT results between two groups were compared.Kaplan-Meier method was used for analyzing for survival rate .Results The objective remission rate of lesions was 10.0%(CR in 1 and PR in 6)in group A and 28.1%(CR in 2,PR in 7)in group B(χ2 =3.259,P=0.071).The mean number of iodine-125 seed was 20.4 ±4.4(14-32) for every patient.The recanalization rate of portal vein was 28.1%in group B higher than 0 in group A(χ2 =7.734,P=0.005). Technical success rate was 100.0% for implantation of iodine-125 seeds strand in the target segment of PVTT.No serious procedure related complications occurred in two group .The mean and median survival time was(153.8 ±9.9) d(95%CI:134.5-173.1) and(150.0 ±10.9) d(95%CI:128.6-171.4) in Group A and(221.5 ±19.2)d 95%CI:183.8-259.1)and(190.0 ±24.7)d 95%CI:141.6-238.4)in Group B, respectively(χ2 =10.973,P=0.001)(HR(A︰B) =2.577,95%CI:1.437-4.623,P=0.001).The 90, 180,360 d cumulative survival rates were 89.7%,28.7%and 0 in group A and 96.8%,56.0%and 15.2%in group B,respectively.In group with recanalization of portal vein (group B1,9 cases),the mean and median survival time were(306.9 ±45.6)d(95%CI:217.5-396.2)and(264.0 ±41.7)d(95%CI:182.3-345.7), respectively and the 90,180,360 d cumulative survival rates were 100.0%,87.5%and 40.0%,respectively. While in group without recanalization of portal vein (group B2,23 cases),the mean and median survival time were(189.5 ±16.5) d (95%CI:157.2-221.9) and (175.0 ±20.4) d (95%CI:134.9-215.1), respectively and the 90,180,360 d cumulative survival rates were 95.5%,43.2%and 6.4%,respectively. There was statistically significant difference between two groups (χ2 =5.105,P=0.024)(HR(B2︰B1) =2.960,95%CI:1.100-7.969,P=0.032).Conclusion TACE combined with endovascular implantation of iodine-125 seeds strand is an effective treatment for HCC with extensive PVTT .

Sensitive and Specific Method for Rapid Identification of Streptococcus pneumoniae Using Real-Time Fluorescence PCR

Treatment of Hepatocellular Carcinoma-associated Portal Vein Tumor Thrombus Using Combination of Portal Vein Stent Insertion and Endovascular Lodine-125 Seed-strip Implantation Followed by Transcatheter Arterial Chemoembolization- Sorafenib

Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis

Irradiation stent with <SUP>125</SUP>I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation

Portal Vein Stenting Combined 125I Particle Implanted Followed by Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas

Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study

[Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein].

Preliminary Results of Main Portal Vein Tumor Thrombus Treated by Endovascular Brachytherapy Combined with Sorafenib

Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

I Know Where You All Are! Exploiting Mobile Social Apps for Large-Scale Location Privacy Probing

Radomized comparative study of hepatocellular carcinoma with extensive portal vein tumor thrombus treated by TACE combined with or without endovascular implantation of iodine-125 seeds strand

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

Combined Iodine-125 Seed Strand, Transarterial Chemoembolizaiton, Lenvatinib and Anti-PD-1 Antibodies Therapy for Unresectable Hepatocellular Carcinoma and Vp4 Portal Vein Tumor Thrombus: A Real-world Study

Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without